Blocking the signal: Brain-derived growth factor may lure lung cancer cells to migrate

by Nancy Fliesler
Blocking the signal: Brain-derived growth factor may lure lung cancer cells to migrate
Researchers have found a molecule that may influence metastasis in adenocarcinoma, the most common type of lung cancer. Credit: Eraxion/iStock

(Medical Xpress)—Ninety percent of lung cancer deaths are caused by the tumor's spread—or metastasis—to other organs. Researchers have now discovered an approach to blocking metastasis in the most common type of lung cancer, adenocarcinoma, that could be added to chemotherapy treatments aimed at shrinking the primary tumor.

Kerstin Sinkevicius, a research fellow at Boston Children's Hospital, started with this question: Is there anything in a lung tumor's environment that makes it metastasize? She sampled tissue from human lymph nodes—the first place cancers typically spread to—to see if the cells there were secreting anything that might lure cancer cells to migrate.

One chemical stood out: a growth factor called brain-derived neurotrophic factor, or BDNF. Secreted near maturing neurons, BDNF is best known for its role in stimulating the developing nervous system.

A brain factor? Yes. When Sinkevicius took BDNF out of the equation, migration of adenocarcinoma cells in culture dropped nearly twofold, suggesting that the cancer cells take advantage of the same signals neurons use.

"A lot of times cancer cells use mechanisms that are built in," explained Sinkevicius.

She and senior investigator Carla Kim, Harvard Medical School associate professor of genetics at Boston Children's, then systematically looked for anything in the primary that might be drawn by BDNF's signal. Could blocking that communication prevent from migrating?

That question led them to a cellular receptor molecule called TrkB. When the researchers took that out of the equation, cell migration was again significantly decreased. And when they deleted TrkB in a live mouse model of adenocarcinoma, only 17 percent of the mice got metastases, as compared with the usual rate of 50 percent.

"The primary tumors were the same, so we think TrkB is specifically important for metastasis," said Sinkevicius. Their findings were published in July in the Proceedings of the National Academy of Sciences.

When adenocarcinoma cells were cultured in low-oxygen conditions—conditions under which lung cancers are more apt to metastasize—TrkB was especially abundant. "Oxygen-deprived tumor cells are stressed out and may be looking to go somewhere else," said Sinkevicius. And TrkB is their ticket.

A two-pronged strategy for lung cancer?

Traditionally, metastasis has been an understudied area in cancer. Companies generally prefer to seek out agents that shrink the primary tumor—a metric that's fairly short term and easily measurable. Antimetastatic agents are a less attractive investment, since metastasis is variable and can take years to occur.

However, compared with previously identified targets for preventing metastasis, TrkB may be easier to hit, said Kim, since chemical TrkB inhibitors are already available and being tested for depression and neurologic disorders such as epilepsy.

"There may be patients for whom TrkB inhibition is particularly useful," she said. "Certain subsets of have higher levels of TrkB."

In their study, she and Sinkevicius found that targeting TrkB was especially effective in the roughly 60 percent of adenocarcinomas that lack two commonly seen mutations, in the genes Kras and EGFR.

And other metastasis-inhibiting compounds could emerge from this work. Kim hopes to do gene-expression studies to see if there are changes in gene activity when TrkB is inhibited. These could help find additional drug targets.

"This is just one hit from the screen Kerstin did," she said. "It demonstrates that you can use a simple cell line-based screen to identify important molecules in metastatic ."

More information: PNAS paper - www.ncbi.nlm.nih.gov/pubmed/24982195

add to favorites email to friend print save as pdf

Related Stories

Cancer researchers identify new metastasis suppressor gene

Jul 14, 2014

(Medical Xpress)—Among patients with deadly cancers, more than 90 percent die because of metastatic spread of their disease. Looking to target a key pathway in order to interfere with the processes that lead to tumor spread, ...

Stopping the spread of breast cancer

Jun 03, 2014

The primary cause of death from breast cancer is the spread of tumor cells from the breast to other organs in the body. Northwestern Medicine® scientists have discovered a new pathway that can stop breast cancer cells from ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

15 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

19 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.